Simulating the Resource and Capacity Impact of Faricimab in an Irish Ophthalmology Clinic

Speaker(s)

Goodwin M1, Burke T2, de Greeff J3
1Roche Products Ireland Limited, Dublin 24, D, Ireland, 2Mater Misericordiae University Hospital, Dublin, D, Ireland, 3Roche Nederland B.V., Woerden, UT, Netherlands

Presentation Documents

OBJECTIVES: As the prevalence of nAMD continues to rise, the growing capacity challenges and high treatment burden place considerable pressure on the healthcare system and can lead to suboptimal outcomes for patients.

We developed a treatment impact model (TIM) to estimate the organisational impact of incorporating faricimab into clinical practice in an Irish Ophthalmology clinic and to assess the impact of new innovative treatments such as faricimab on clinic capacity, as well as the potential to treat additional patients.

METHODS: Patient data included in our de-novo TIM was sourced from an Irish ophthalmology clinic and includes drug and administration costs, annual injection frequencies, and time spent by health care professionals in treatment administration. Data for faricimab was informed by the TENAYA/LUCERNE clinical trial.

Treatment impact was assessed by assuming patients switched from the current standard of care (SOC), bevacizumab, to faricimab. A number of treatment switch scenarios from bevacizumab to faricimab were explored, ranging from 10-50%.

RESULTS: For every 100 patients switched from bevacizumab to faricimab, 345 less IVT treatments are estimated to be administered in clinic per year. There is potential for time savings of 58 hours of ophthalmologist time and 115 hours of nurse time per year.

CONCLUSIONS: These are the first results published examining the impact of switching patients from bevacizumab to faricimab in an Irish ophthamology clinic.

Faricimab has the potential to reduce the high treatment burden on Irish patients resulting from less durable treatments such as bevacizumab, and increase clinic capacity in Irish ophthalmology clinics to allow for the treatment of additional patients.

Code

EE115

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)